Erica Oberg's telehealth GLP-1 Treatments, Semaglutide or Tirzepatide medical weight loss program in La Jolla, CA starts to make a lot of sense
#COPD #RespiratoryMedicine #ClinicalPharmacology #MedEd #HealthcareEducation #Pulmonology #Pharmacology #PDE4Inhibitors To view or add a comment, sign in Last week at ATTD, Abbott shared results from the UKled FreeDM2 study an important moment for people living with type 2 diabetes and for the NHS
This point is effectively made in a recently conducted large trial, which states that, our understanding of the mechanisms of cardiovascular protection with [the GLP-1 agonist] semaglutide remains speculativeclinical benefit is [thought to be] achieved through multiple interrelated pathways. Acknowledgement of this evidence gap prompted our lab, through use of a large animal model of CAD that replicates the features of disease as it occurs in humans, to investigate the cardiac consequences of semaglutide administration
This approach prevents overstimulation and allows your tissues to reset and respond more favorably during active treatment phases
5/5: ~0.167 mg tes + ~0.167 mg ipa
For SAD, Aplenzin is also started at 174mg